Ionis pharmaceuticals, inc.IONS.US Overview
IONS Overall Performance
IONS AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
IONS Current Performance
0.05%
Ionis pharmaceuticals, inc.
-0.47%
Avg of Sector
-0.64%
S&P500
IONS Key Information
IONS Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
IONS Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
IONS Profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Price of IONS
IONS FAQ
When is IONS's latest earnings report released?
The most recent financial report for Ionis pharmaceuticals, inc. (IONS) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IONS's short-term business performance and financial health. For the latest updates on IONS's earnings releases, visit this page regularly.
What is the operating profit of IONS?
According to the latest financial report, Ionis pharmaceuticals, inc. (IONS) reported an Operating Profit of 139.82M with an Operating Margin of 30.93% this period, representing a growth of 311.55% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is IONS's revenue growth?
In the latest financial report, Ionis pharmaceuticals, inc. (IONS) announced revenue of 452.05M, with a Year-Over-Year growth rate of 100.69%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does IONS have?
As of the end of the reporting period, Ionis pharmaceuticals, inc. (IONS) had total debt of 1.42B, with a debt ratio of 0.48. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does IONS have?
At the end of the period, Ionis pharmaceuticals, inc. (IONS) held Total Cash and Cash Equivalents of 297.3M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does IONS go with three margins increasing?
In the latest report, Ionis pharmaceuticals, inc. (IONS) achieved the “three margins increasing” benchmark, with a gross margin of 99.1%%, operating margin of 30.93%%, and net margin of 27.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IONS's profit trajectory and future growth potential.
Is IONS's EPS continuing to grow?
According to the past four quarterly reports, Ionis pharmaceuticals, inc. (IONS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of IONS?
Ionis pharmaceuticals, inc. (IONS)'s Free Cash Flow (FCF) for the period is 139.03M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 210.24% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of IONS?
The latest valuation data shows Ionis pharmaceuticals, inc. (IONS) has a Price-To-Earnings (PE) ratio of -25.77 and a Price/Earnings-To-Growth (PEG) ratio of -0.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.